EMAIL THIS PAGE TO A FRIEND

Cancer immunology, immunotherapy : CII

Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.


PMID 24893857

Abstract

Antibody-cytokine fusion proteins ("immunocytokines") represent a promising class of armed antibody products, which allow the selective delivery of potent pro-inflammatory payloads at the tumor site. The antibody-based selective delivery of interleukin-2 (IL2) is particularly attractive for the treatment of metastatic melanoma, an indication for which this cytokine received marketing approval from the US Food and drug administration. We used the K1735M2 immunocompetent syngeneic model of murine melanoma to study the therapeutic activity of F8-IL2, an immunocytokine based on the F8 antibody in diabody format, fused to human IL2. F8-IL2 was shown to selectively localize at the tumor site in vivo, following intravenous administration, and to mediate tumor growth retardation, which was potentiated by the combination with paclitaxel or dacarbazine. Combination treatment led to a substantially more effective tumor growth inhibition, compared to the cytotoxic drugs used as single agents, without additional toxicity. Analysis of the immune infiltrate revealed a significant accumulation of CD4(+) T cells 24xa0h after the administration of the combination. The fusion proteins F8-IL2 and L19-IL2, specific to the alternatively spliced extra domain A and extra domain B of fibronectin respectively, were also studied in combination with tumor necrosis factor (TNF)-based immunocytokines. The combination treatment was superior to the action of the individual immunocytokines and was able to eradicate neoplastic lesions after a single intratumoral injection, a procedure that is being clinically used for the treatment of Stage IIIC melanoma. Collectively, these data reinforce the rationale for the use of IL2-based immunocytokines in combination with cytotoxic agents or TNF-based immunotherapy for the treatment of melanoma patients.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A7302
4-Acetamidophenol, 98%
C8H9NO2
A7085
Acetaminophen, BioXtra, ≥99.0%
C8H9NO2
A3035
Acetaminophen, analytical standard
C8H9NO2
A5000
Acetaminophen, meets USP testing specifications, 98.0-102.0%, powder
C8H9NO2
1003009
Acetaminophen, United States Pharmacopeia (USP) Reference Standard
C8H9NO2
PHR1005
Acetaminophen, Pharmaceutical Secondary Standard; Certified Reference Material
C8H9NO2
A-064
Acetaminophen solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C8H9NO2
HPA043014
Anti-RPL19 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SRP6170
IL-2 human, recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE)
SRP3085 IL-2 human, Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), cell culture tested
57600 Interleukin-2 human, ≥98.0% (GE), recombinant, expressed in E. coli, ~10000 U/mL
I2644 Interleukin-2 human, IL-2, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
I7908 Interleukin-2 human, recombinant, expressed in Pichia pastoris, suitable for cell culture
H7041 Interleukin-2 human, IL-2, recombinant, expressed in HEK 293 cells, cell culture tested, endotoxin tested
WH0006143M1
Monoclonal Anti-RPL19 antibody produced in mouse, clone 3H4, purified immunoglobulin, buffered aqueous solution
P0300000
Paracetamol, European Pharmacopoeia (EP) Reference Standard
C8H9NO2
T7539
Tumor Necrosis Factor-α from mouse, TNF-α, recombinant, expressed in E. coli, powder, suitable for cell culture